Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LODE | CLUSTER | bullish | 7/10 | Two Comstock Inc. insiders, CFO Judd Merrill and Director Leo Drozdoff, collectively purchased $95K worth of shares in o | Apr 1, 2026 |
| APRE | CLUSTER | bullish | 6/10 | Two corporate insiders at Aprea Therapeutics, CFO John Hamill and Director Richard Peters, collectively purchased $125K | Apr 1, 2026 |
| ALT | CLUSTER | neutral | 4/10 | Two top executives at Altimmune, the CEO and CFO, collectively purchased $79K worth of stock in early April 2026, signal | Apr 1, 2026 |
| HBIO | CLUSTER | neutral | 3/10 | Analysis based on filing metadata only, document content was unavailable. This is an insider trading cluster filing for | Apr 1, 2026 |
| SLNO | CLUSTER | neutral | 3/10 | Analysis based on filing metadata only, document content was unavailable. Two insiders at Soleno Therapeutics Inc. (SLNO | Mar 31, 2026 |
| ZBIO | CLUSTER | mixed | 6/10 | Analysis based on filing metadata only, document content was unavailable. However, a recent insider trading cluster show | Mar 31, 2026 |
| IMNM | CLUSTER | mixed | 5/10 | Analysis based on filing metadata only, document content was unavailable. Recent insider activity shows CEO Clay Siegall | Mar 31, 2026 |
| IBO | CLUSTER | bearish | 4/10 | Analysis based on filing metadata only, document content was unavailable. This insider trading cluster involves recent o | Mar 30, 2026 |
| LQDA | CLUSTER | neutral | 3/10 | Analysis based on filing metadata only, document content was unavailable. This filing relates to an insider trading clus | Mar 30, 2026 |
| NUVL | CLUSTER | bearish | 6/10 | Analysis based on filing metadata only, document content was unavailable. Cross-filing context reveals a recent insider | Mar 30, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | United Therapeutics insiders, including CEO Martine Rothblatt and CFO James Edgemond, conducted a series of derivative e | Mar 27, 2026 |
| CORT | CLUSTER | neutral | 3/10 | Corcept Therapeutics CEO Joseph Belanoff sold $1.31M worth of shares in a single open-market transaction. This represent | Mar 27, 2026 |
| IBIO | CLUSTER | neutral | 3/10 | iBio's Chief Legal Officer, Marc Banjak, purchased 12,500 shares in the open market for approximately $20,531, marking a | Mar 27, 2026 |
| RVMD | CLUSTER | neutral | 4/10 | Anthony Mancini, an insider at Revolution Medicines, exercised options for 74,900 shares and sold 1,800 shares on the op | Mar 26, 2026 |
| ACAD | CLUSTER | neutral | 4/10 | Multiple C-suite executives at Acadia Pharmaceuticals, including the CEO, CFO, and other senior officers, conducted open | Mar 26, 2026 |
| GNLX | CLUSTER | neutral | 3/10 | Five GENELUX Corp insiders, including the CEO and CTO, sold shares in the past week, with total open-market sales amount | Mar 26, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | United Therapeutics insiders executed a cluster of derivative exercises and open-market sales over the past week, led by | Mar 26, 2026 |
| CYRX | CLUSTER | neutral | 3/10 | Cryoport CEO Jerrell Shelton exercised options for 50,000 shares and sold 2,894 shares in open market for $23,673, while | Mar 25, 2026 |
| KYMR | CLUSTER | bearish | 6/10 | Kymera Therapeutics COO Chadwick Jeremy G conducted a series of derivative exercises and open-market sales over the past | Mar 25, 2026 |
| RXRX | CLUSTER | neutral | 3/10 | Director Christopher Gibson sold 40,000 shares in an open-market transaction for $130,000, while also converting derivat | Mar 25, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | Over the past seven days, key insiders at United Therapeutics, including CEO Martine Rothblatt and CFO James Edgemond, e | Mar 25, 2026 |
| BCAX | CLUSTER | neutral | 4/10 | Multiple C-suite executives at Bicara Therapeutics (BCAX) exercised stock options and sold shares in the open market ove | Mar 24, 2026 |
| ROIV | CLUSTER | neutral | 2/10 | Jennifer Humes, Chief Accounting Officer of Roivant Sciences Ltd., surrendered 14,526 shares to cover tax obligations du | Mar 24, 2026 |
| OKUR | CLUSTER | neutral | 2/10 | The CEO and CFO of OnKure Therapeutics sold small amounts of stock in the open market, totaling $1,609 in combined proce | Mar 24, 2026 |
| CRSP | CLUSTER | neutral | 3/10 | CRISPR Therapeutics CFO Prasad Raju sold $173,460 worth of shares in an open-market transaction, while both the CFO and | Mar 24, 2026 |
| TARS | CLUSTER | bearish | 7/10 | Seven executives at Tarsus Pharmaceuticals, including the CEO, COO, and CMO, sold shares in a coordinated open-market cl | Mar 24, 2026 |
| CORT | CLUSTER | neutral | 4/10 | Chief Development Officer William Guyer exercised stock options and sold 11,767 shares in the open market for approximat | Mar 24, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | United Therapeutics CEO Martine Rothblatt and EVP Paul Mahon exercised stock options and sold shares in the open market, | Mar 24, 2026 |
| STOK | CLUSTER | bearish | 6/10 | Seven open-market share sales by four insiders at Stoke Therapeutics over the past week, including the CFO, Chief Medica | Mar 24, 2026 |
| TWST | CLUSTER | neutral | 3/10 | Three insiders at Twist Bioscience sold shares in a coordinated open-market transaction on March 20, 2026, including CEO | Mar 24, 2026 |